NeuroQ Review 2026: They Ran a Real Trial — Then Marketed the Wrong Number From It

Here is the registration, which anyone can read. **NCT06672094** — "A Randomized, Triple-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of NeuroQ on Cognitive Function in Healthy Adults with Self-reported Memory Problems." Sponsor: LifeSeasons Inc.

NeuroQ's product pages lead with this: **"97% of participants saw improvement in memory, focus, or concentration in the first 7 days."** Alongside it, "+10% Processing Speed." The framing is "Double-blind. Placebo-controlled. The actual NeuroQ formula — tested with the same computerized neurocognitive testing used by pharmaceutical companies." Four problems, in ascending order of importance. **It is the secondary timepoint, not the primary.** The registered primary outcome is measured at **60 days**. Day 7 is a secondary outcome. Leading with a secondary endpoint while the primary goes unmentioned is the oldest tell in results reporting. **It is a within-group responder rate, not a between-group difference.** "97% of participants saw improvement" describes how many people in the NeuroQ arm scored better than they did at baseline. The registered outcome is "the difference in change in cognitive function **between NeuroQ and placebo**." Those are completely different quantities. The whole point of running a placebo arm is that the within-group number is uninformative without it. **And in cognitive testing, the within-group number is close to meaningless**, because of practice effects. When you administer a computerised neurocognitive battery twice a week apart, most people score better the second time simply because they have done it before. A 97% improvement rate in the treatment arm is only impressive if the placebo arm's rate was substantially lower—and if it wasn't, the honest conclusion is that the test got easier, not that the brain got better. LifeSeasons has that placebo number. It designed the study specifically to produce it. It is not in the marketing. **The enrolment was 40 people.** Twenty or so per arm. That is a pilot-scale study, appropriate for generating a signal and inadequate for the confident claims built on it. **And the results have never been posted.** The trial completed on July 23, 2024. As of July 30, 2026—more than two years later—no results are posted to the ClinicalTrials.gov record, and we could not find a peer-reviewed publication of it.

NeuroQ discloses every ingredient and amount with no proprietary blend, which is worth stating plainly as a credit. Two capsules daily, stimulant-free.

Of the six ingredients, ginkgo biloba is the one with the largest and most definitive body of evidence—and that is not good news for the formula. The **Ginkgo Evaluation of Memory (GEM) study** remains the largest trial ever conducted on ginkgo and dementia. Published in *JAMA* in November 2008 by DeKosky and colleagues, it randomised **3,069 community volunteers aged 75 and over**—2,587 with normal cognition and 482 with mild cognitive impairment—to **240 mg of ginkgo biloba daily or placebo**, across five US academic medical centres, with a median follow-up of **6.1 years**. The result: ginkgo was **ineffective** at reducing the development of dementia or Alzheimer's disease. A companion analysis found no effect on the rate of cognitive decline either. NeuroQ contains **120 mg of ginkgo**—half the dose that failed in the largest and longest trial ever run on it. That does not mean ginkgo does nothing for anyone. GEM tested dementia *prevention* in the elderly, which is a different question from short-term cerebral blood flow or subjective mental clarity in a 55-year-old, and some smaller trials have found modest effects on cognitive symptoms. But when a formula's marketing invokes long-term brain protection, the trial that directly tested long-term brain protection is the relevant evidence, and it was negative. The rest of the panel is more defensible and less studied. **Phosphatidylserine** has the best supporting literature of the six for age-associated memory complaints, though trials typically use 300 mg daily and NeuroQ provides 100 mg. **Coffee fruit extract (NeuroFactor)** is marketed on raising BDNF, based on small manufacturer-linked studies; the connection between an acute serum BDNF rise and any durable cognitive benefit is not established. **Gotu kola**, **curcumin** and **propolis** have preclinical and mechanistic support and thin human outcome data at these doses. Curcumin at 250 mg without a bioavailability enhancer such as piperine or a phytosome carrier is also poorly absorbed.

NeuroQ describes its formulator as "Dr. Dale Bredesen, M.D. · Neurologist · UCLA & Buck Institute." Those credentials are accurate. Bredesen is a genuinely accomplished neuroscientist—his laboratory work on dependence receptors and programmed cell death is real, cited science, and he was the founding president of the Buck Institute for Research on Aging. The contested part is the clinical protocol. Bredesen's ReCODE approach—a multi-component personalised programme for cognitive decline—became widely known through case series rather than controlled trials, and drew sustained criticism in the neurology literature, including in *Lancet Neurology*, on the grounds that uncontrolled observations of 10 to 100 patients cannot establish causality. The Alzheimer Society of Canada has published a position stating the protocol offers false hope of reversing Alzheimer's disease, and the general position across the field remains that no lifestyle programme, medication or system has been clinically validated to reverse Alzheimer's. In December 2025 Bredesen and colleagues released a preprint of a nine-month randomised controlled trial in 73 patients with MCI or early dementia—the first RCT of the approach. Reported cognitive gains were substantial, but the reported limitations are significant: no blinding of participants, physicians or health coaches, and no significant difference on the MoCA, the most widely used clinical measure. None of which is a verdict on this supplement. NeuroQ is a six-ingredient capsule, not the ReCODE protocol, and the site's phrase "the same science as the Bredesen 7 protocol" is doing a lot of associative work. The relevant point for a buyer is narrower: a credentialed neurologist's name on a bottle is a marketing asset, not evidence about what is in the bottle. The trial is the evidence, and the trial's primary result is unpublished.

NeuroQ sells Memory & Focus Extra Strength at $79.95 for 30 days, describing it as "Everything the original does — at full potency… in a stronger daily dose for those who want the maximum." On the Extra Strength product page itself, under the heading "All six ingredients above. Every milligram on the label. No proprietary blends," the amounts listed are: **Phosphatidylserine 100 mg, Coffee Fruit Extract 100 mg, Gotu Kola 250 mg, Ginkgo Biloba 120 mg, Turmeric 250 mg, Bee Propolis 75 mg.** Those are the same six numbers as the standard formula. We do not think the two products are actually identical. A third-party retail listing for NeuroQ Extra Strength gives a total of 1,020 mg per two capsules, whereas the standard formula's listed amounts sum to 895 mg—so something differs by roughly 125 mg. Some retail listings for a NeuroQ "Extra Strength" also name **Huperzine A**, which does not appear anywhere on the current neuroq.com page. We could not obtain a clean, current Supplement Facts panel for Extra Strength to resolve this. So we are reporting a documentation failure rather than a formulation one: **a product sold as "Extra Strength" at $79.95 displays, on its own page, the exact per-ingredient amounts of the cheaper standard version.** A buyer cannot tell from the brand's own site what they are paying extra for.

NeuroQ is expensive. Prices from the live product feed and product pages on July 30, 2026:

We have reviewed a long run of supplement brands whose refund policies exclude anything you have opened. NeuroQ's is the opposite, and it deserves to be quoted in full: **"60-Day Money-Back Guarantee. No risk. No fine print. No awkward phone call. Try NeuroQ for 60 days. If it's not right for you — for any reason — send it back. Even if the bottle is empty. Full refund of the purchase price. No questions. No runaround."** Sixty days, works even if you have finished the bottle, and the company publishes a phone number (1-800-513-2151) and an email address. On paper that is the strongest consumer-facing guarantee in this category we have written about, and it substantially de-risks trying the product. Then there is the other side, and it is the reason this section is not simply a compliment. **Cancellation is by phone.** The subscription benefits list reads "Cancel anytime by phone." There is no documented self-serve cancel path. For a product marketed to people in their sixties and seventies who are worried about their memory, making cancellation a phone-only process is a design choice with a predictable outcome. LifeSeasons' Better Business Bureau file is small—**4 complaints in three years, 1 in the last twelve months**, and the company is not BBB accredited. That is a low complaint volume and we are not going to inflate it. But the pattern in the complaints that exist is consistent, and the most recent one, filed **March 27, 2026, is recorded as unanswered**. It reads: *"I signed up for a supplement and was put on an auto send. I tried to call and cancel but their telephone number options all say not working."* That is the specific failure mode of a phone-only cancellation policy, reported by a customer, and left without a response. An earlier complaint reads: *"They keep sending me these pills I no longer wanted since I cancelled and taking my money every month."*

**NeuroQ might suit you if:** you want a fully-disclosed, no-proprietary-blend cognitive formula and you are comfortable that the evidence for it is a 40-person unpublished trial; you specifically want phosphatidylserine, gotu kola and curcumin in one capsule rather than buying three bottles; the 60-day empty-bottle guarantee makes trying it feel low-risk; and $34.97–$69.95 a month is comfortable for you. **Look elsewhere if:** you are buying it because "clinically tested" implied more than a 40-person study with unposted results; you are on a budget, because the individual ingredients are available far more cheaply and phosphatidylserine at the studied 300 mg dose costs less on its own than this whole formula; you or the person you are buying for takes donepezil, galantamine or rivastigmine, and you cannot confirm what is in the Extra Strength bottle; you take an anticoagulant or antiplatelet drug, since ginkgo has a bleeding-risk interaction and 120 mg is a real dose; or you would find a phone-only cancellation process difficult. **And most importantly:** if the reason you are shopping for this is that you or a family member has noticed genuine memory changes, please make a doctor's appointment. Memory complaints have a long list of treatable causes—thyroid disease, B12 deficiency, depression, sleep apnoea, medication side effects—and every one of them is found by evaluation, not by a supplement. A $69.95 monthly capsule that delays that appointment is the expensive outcome here, not the price.

**Does NeuroQ have a real clinical study?** Yes, and that is unusual. LifeSeasons registered NCT06672094, a randomised, triple-blind, placebo-controlled trial of the finished NeuroQ formula in 40 adults with self-reported memory problems, completed July 2024. The caveats: 40 participants is pilot scale, the sponsor is the manufacturer, no results have been posted to the registry as of July 30, 2026, and we found no peer-reviewed publication. **What does the "97% saw improvement in 7 days" claim mean?** It appears to be a within-group responder rate from a secondary endpoint. The registered primary outcome is the difference between NeuroQ and placebo at 60 days. "97% of participants improved" says nothing about the placebo group, and in repeated computerised cognitive testing most people improve on the second sitting through practice effects. The between-group number is the one that matters and it has not been published. **Is NeuroQ the Bredesen protocol?** No. It is a six-ingredient supplement that Dr Dale Bredesen helped formulate. The site's phrase "the same science as the Bredesen 7 protocol" links the two by association. Bredesen's ReCODE protocol is a separate, multi-component programme that has itself been criticised for a thin controlled-trial base. **Does NeuroQ treat Alzheimer's?** No, and to its credit the company does not claim it does. No supplement is approved to treat, prevent or reverse Alzheimer's disease, and the FDA and FTC have taken enforcement action against companies that make that claim. **How much does NeuroQ cost?** $89.95 for a single 30-day supply, $69.95 on a monthly subscription, or as low as $34.97 per bottle on a six-month plan. Extra Strength is $79.95 for 30 days. **Can I get a refund?** Yes, and the policy is unusually generous: 60 days, full refund of the purchase price, valid "even if the bottle is empty." **How do I cancel a NeuroQ subscription?** By phone, on 1-800-513-2151. There is no documented self-serve cancellation. A BBB complaint filed in March 2026 and recorded as unanswered states the phone menu options were not working. Follow any call with a confirming email and check your statements. **Does NeuroQ contain caffeine?** Essentially none. The coffee fruit extract is specified at under 1 mg of caffeine, and the product is marketed as stimulant-free. **Does it interact with medications?** Potentially. Ginkgo biloba at 120 mg has a recognised bleeding-risk interaction with anticoagulants and antiplatelet drugs. Curcumin can also affect platelet function. And if the Extra Strength bottle you receive lists Huperzine A, that is an acetylcholinesterase inhibitor and should not be combined with donepezil, galantamine or rivastigmine without medical advice. Show the label to your pharmacist.